期刊文献+

生物等效性试验中生物分析的关键问题 被引量:4

Key questions in bioanalysis in bioequivalence study
原文传递
导出
摘要 生物等效性试验是药品研发和评价的一个重要内容。生物等效性试验首选药动学研究的方法,药动学研究则必然涉及到生物分析,因此生物分析对于生物等效性试验具有举足轻重的作用,其结果的可靠性将直接影响生物等效性试验的质量。但我国目前却没有完整、独立的生物分析方面的指导原则。基于上述原因,我们根据国内外的相关指导原则,并尽可能结合我们的实际工作,探讨生物等效性试验中生物分析需注意的关键问题。 Bioequivalence study is an important aspect of medicinal product development and evaluation. Pharmacokinetic method, as the most preference used to evaluate bioequivalence, necessarily involves measurement of drug concentrations in biological matrices, which is bioanalysis. The reliability of bioanalysis results directly affects the quality of bioequivalence study. However, there is no complete and specialized guidance related to bioanalysis issued in China. Therefore, in this paper, several key questions in bioanalysis in bioequivalence study were discussed based on related guidelines and our experiences.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2014年第3期157-163,共7页 Chinese Journal of New Drugs and Clinical Remedies
关键词 生物等效性 生物分析 分析物 bioequivalence bioanalysis analyte
  • 相关文献

参考文献28

  • 1CFDA.化学药物制剂人体生物利用度和生物等效性研究技术指导原则[EB/OL].(2007-08-23)[2008-04-29].http://www.cde.org.cn/zdyz.do?method=largePage&id:2066.
  • 2EMA. Guideline on bioanalytical method validation [EB/OL]. (2011-07 -21 ) [2012 -10-22]. http ://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2011/08/WC50010 9686.pdf.
  • 3FDA. Guidance for industry: bioanalytical method validation [EB/ OL]. (2001 -05 ) [2011 -03 - 10]. http ://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/ucm 070107.pdf.
  • 4钟大放,李高,刘昌孝.生物样品定量分析方法指导原则(草案)[J].药物评价研究,2011,34(6):409-415. 被引量:58
  • 5CFDA.化学药物非临床药代动力学研究技术指导原则[EB/OL].(2007-08-23)[2008-04-29].http://www.cde.org.cn/zdyz.do?method=largePage&id=2056.
  • 6CFDA.化学药物临床药代动力学研究技术指导原则[EB/OL].(2007-08-23)[2008-04-29].http://www.cde.org.cn/zdyz.do?method=largePage&id=2070.
  • 7EMA. Guideline on the investigation of bioequivalence [EB/OL]. (2010-08-01) [2013-02-25]. http://www.ema.europa.eu/docs/ en_GB/ document_library/Scientific_guideline/2010/01/W C50007 0039.pdf.
  • 8EMA. Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples (draft) [EB/ OL]. (2011-02-28) [2013-02-25]. http://www.ema.europa.eu/docs/ en_GB / document_library / Regulatory_and_procedural~,uideline / 2010/09/WC500096987.pdf.
  • 9FDA. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations (Revision 1 ) [EB/OL]. (2003-03) [2011-05-27]. http ://www.fda.gov/downloads/Drugs/GuidanceComplianceRegula - toryInformation/Guidances/ucm070124.pdf.
  • 10FDA. Guidance for industry: bioequivalence recommendations for specific products [EB/OL]. (2010-06) [2012-05-30]. http:// www. fda. gov / downloads / Drugs / GuidanceComplianceRegulatory Information/Guidances/UCM072872.pdf.

二级参考文献17

  • 1邸晓辉,杨永革,梅巍,刘静,许雪廷.阿托伐他汀钙胶囊的人体生物等效性研究[J].解放军药学学报,2005,21(4):262-265. 被引量:8
  • 2Lennern(a)s H. Clinical phannacokinetics of atorvastatin[J].Clinical Pharmacokinetics,2003.1141-1160.
  • 3Jacolsen W,Kuhn B,Soldner A. Lactoizafion is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin[J].Drug Metabolism and Disposition,2000.1369-1378.
  • 4Liu YM,Pu HH,Liu GY. Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets:a single-dose,randomized-sequence,open-label,two-period crossover study in healthy fasted Chinese adult males[J].Clinical Therapeutics,2010.1396-1407.
  • 5He BX,Shi L,Qiu J. Quantitative determination of atorvastatin and ortho-hydrexy atorvastatin in human plasma by liquid chromatography tandem mass spectrometry and pharmacokinetic evaluation[J].Experimental and Clinical Psychopharmacology,2010.481-487.
  • 6Kantola T,Kivist(o) KT,Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin[J].Clinical Pharmacology and Therapeutics,1998.58-65.
  • 7Mendoza L,Hajdúch M,Plausinaitis R. Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers[J].Die Pharmazie,2006.805-806.
  • 8Lins RL,Matthys KE,Verpooten GA. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients[J].Nephrology Dialysis Transplantation,2003.967-976.
  • 9Borek-Dohalsky V,Huclova J,Barrett B. Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study[J].Analytical Biochemistry,2006.275-285.
  • 10Bullen WW,Miller RA,Hayes RN. Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin,ortho-hydroxy atorvastatin,and para-hydroxy atorvastatin in human,dog,and rat plasma[J].Journal of the American Society For Mass Spectrometry,1999.55-66.

共引文献65

同被引文献64

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部